Manufacturer record
DYCOTT Healthcare: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by DYCOTT Healthcare (Himachal Pradesh) was declared Not of Standard Quality in May 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: DYC-24007, Rabeprazole Sodium (EC) & Domperidone (SR) Capsules (Dorsai) (exp Mar 2026). CDL, Kolkata (CDSCO lab) found it not of standard quality: Dissolution of Rabeprazole Sodium (acid stage), Dissolution of Rabeprazole Sodium (buffer stage) and Assay of Rabeprazole Sodium. Listed in the May 2025 alert.
Records by type
1 record linked to DYCOTT Healthcare in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Rabeprazole Sodium (EC) & Domperidone (SR) Capsules (Dorsai) | Batch DYC-24007Mfg Apr 2024 · Exp Mar 2026 | Dissolution of Rabeprazole Sodium (acid stage), Dissolution of Rabeprazole Sodium (buffer stage) and Assay of Rabeprazole SodiumAssay | CDL, KolkataCDSCO lab | May 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.